



Emergent BioSolutions to Release Fourth Quarter and Full Year 2009 Financial Results and Conduct a Conference Call on March 4, 2010

January 25, 2010

ROCKVILLE, Md., Jan 25, 2010 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for fourth quarter and full year 2009 on Thursday, March 4, 2010, after market close.

Company management will host a conference call at 5:00 pm Eastern on March 4, 2010 to discuss the financial results for the fourth quarter and full twelve months of 2009, recent business developments and the forecast for 2010. The conference call will be accessible by dialing **888/680-0893** or **617/213-4859** (international) and providing passcode **15824424**. A webcast of the conference call will be accessible from the Company's website at <http://www.emergentbiosolutions.com/>, under "Investors".

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration, while not mandatory, can be accessed using the following website:

<https://www.theconferencingervice.com/prereg/key.process?key=PWUCNRR6E>

A replay of the conference call will be accessible, approximately one hour following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using the passcode 94837956. The replay will be available through March 18. The webcast will be archived on the company's website, <http://www.emergentbiosolutions.com/>, under "Investors".

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax^(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at <http://www.emergentbiosolutions.com/>.



SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

Investors Contact:

Robert G. Burrows

Vice President, Investor Relations

301-795-1877

BurrowsR@ebsi.com

or

Media Contact:

Tracey Schmitt

Vice President, Corporate Communications

301-795-1800

SchmittT@ebsi.com